Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
Avatar

Chemotherapy vs. Chemo Free in Indolent Non-Hodgkin Lymphoma - Can We Improve Outcomes With Emerging Agents?

By Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019) FEATURING Nathan H. Fowler
By Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019) FEATURING Nathan H. Fowler
0 views
October 18, 2019
Comments 0
Login to view comments. Click here to Login

Featured Video

24:44
Indy Hematology Review

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Feat. R. Birhiray

Featured Video

01:29
Incyte

Targeting CSF-1R to Manage Inflammation and Fibrosis in GVHD

Recommended

AUTOPLAY
27:47
Indy Hematology Review

Current Advances in the Treatment of Aggressive B- and T-Cell Lympho…

Feat. S. Smith
08:18
Insights from 2023 ASH Annual Meeting

Treatment Strategies for Hematocrit Control in PV

Feat. A. Zhou
17:07
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "Comparative Review of Toxicities and Their…

Feat. M. Minnema
29:26
Massachusetts General Hospital Cancer Center

Practice-Changing Updates in DLBCL and HL

Feat. J. Erika Haydu
15:14
Icahn School of Medicine at Mount Sinai

Safety Profile of Ruxolitinib in Patients With MF

Feat. D. Tremblay
17:21
Daniel Addison

Cardiovascular Considerations With (Contemporary) BTKi in the Treatm…

09:27
ASH 2022 Conference Coverage

MAJIC-PV Trial: Ruxolitinib vs. Best Available Therapy for PV Intole…

Feat. M. McMullin
05:38
GRACE

Epcoritamab in NHL - Incidence and Management of CRS

Feat. T. Phillips
16:25
Northwestern Medicine Oncology and Hematology

Diagnosis and Goals of Therapy in PV

Feat. B. Stein
06:51
Insights from 2023 ASH Annual Meeting

Prevalence and Prediction of Ruxolitinib Treatment Emergent Thromboc…

Feat. D. Tremblay
37:26
Basem William

Cutaneous Lymphoma 101: Overview on Diagnosis, Staging and Prognosis

26:58
Total Health

Update on Cellular Therapy in Lymphoma

Feat. B. Randolph
16:27
Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient

Therapeutic Advances in T-Cell Lymphoma in 2024

Feat. S. Barta
22:38
Indy Hematology Review

Immune Effector Cell Therapy for Lymphoid Malignancies: What to Do a…

Feat. T. Phillips
55:12
University of Colorado Division of Hematology

A Personalized Approach for T-Cell Lymphomas

Feat. B. Haverkos
33:11
Total Health

Bispecific Antibodies and CAR T-Cells for NHL: Challenges and Opport…

Feat. K. Komanduri
10:49
Monia Marchetti

Using Cytoreductive Therapy to Prevent Cardiovascular Events in Pati…

13:04
Winship Cancer Institute - Emory University

Treatment-Related Quality of Life in MF

Feat. A. Hunter
13:58
Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: Intrathecal Rituximab + Dex for Refractory Sanctu…

Feat. M. Salamoon
42:09
University of Colorado Department of Medicine

Immunotherapy in Lymphomas: The Present and the Future

Feat. M. Kamdar